Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03564769 · ClinicalTrials.gov registry record · NA
Evaluation Study of SPOTme® Skin Cancer Screenings
A NA study, sponsored by Harvard School of Public Health (HSPH).
- Completed
- Registry status
- NA
- Development phase
- 431
- Enrollment target
NCT03564769: Completed NA study, sponsored by Harvard School of Public Health (HSPH).
NCT03564769 is a NA study that has completed, run by Harvard School of Public Health (HSPH). The registered enrollment target is 431 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03564769, a NA study, has completed, sponsored by Harvard School of Public Health (HSPH).
- COMPLETED
- Registry status
- NA
- Development phase
- 431 participants
- Enrollment target
Study Summary
This study evaluates the impact of the AAD SPOTme® skin cancer screening events on attendees' skin cancer prevention and detection behaviors. This study will also evaluate whether an educational intervention will improve post-screening engagement of attendees with dermatologists.
Primary Outcome
Self-report of a physician skin examination will be defined as a health care provider examining the patient's entire body for any sign of skin cancer during the period following patient's receipt of an AAD SPOTme® skin cancer screening to the baseline assessment.
Interventions
- BEHAVIORAL Intervention Arm
- OTHER AAD SPOTmeⓇ skin cancer screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 431 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2019-06-01 |
| Phase | NA |
What the finished NCT03564769 record still lists
NCT03564769 is an interventional study that assigns participants to a tested intervention. The registered 431 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 2 interventions - of which Intervention Arm is the first listed.
NCT03564769 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03564769 about?
NCT03564769 is a clinical study titled "Evaluation Study of SPOTme® Skin Cancer Screenings". This study evaluates the impact of the AAD SPOTme® skin cancer screening events on attendees' skin cancer prevention and detection behaviors. This study will also evaluate whether an educational intervention will improve post-screening engagement of attendees with dermatologists.
What is the current status of trial NCT03564769?
This trial is currently completed. It is a NA study. The enrollment target is 431 participants. The study started on 2017-12-01. Estimated completion is 2019-06-01.
What interventions are being tested in trial NCT03564769?
The interventions under investigation include: Intervention Arm (BEHAVIORAL), AAD SPOTmeⓇ skin cancer screening (OTHER).
Who is sponsoring clinical trial NCT03564769?
This trial is sponsored by Harvard School of Public Health (HSPH), which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03564769's enrollment target sits among peer trials
431 235th of 2000 higher than 1,766 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05128890 · 431 participants
Evaluation of Resection Techniques for Pancreatic Tumors
- NCT05271240 · 432 participants · Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- NCT05365815 · 432 participants · NA
Melanated Group Midwifery Care (MGMC)
- NCT05499507 · 432 participants · NA
The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI